The data on the coronavirus pandemic is updated daily
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
his Inter Action Review report for the COVID-19 outbreak in Mauritius documents and assesses the country’s capacity to respond to the outbreak and identifies the best practices, strengths, gaps and challenges of the national response. Areas requiring improvements or sustained actions have been ide...ntified across the 9 strategic pillars of World Health Organization (WHO)’s COVID-19 Strategic Preparedness and Response Plan and an additional pillar for the country’s response beyond health. On an overall, the review aims to enhance and sustain the national response with a particular focus on strengthening the health systems.
more
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...de la COVID-19 par le public dans les États membres de l’Union africaine. Actuellement, il n’y a : 1. Aucune preuve scientifique provenant d’études précliniques sur l’effet thérapeutique de l’ivermectine pour le traitement de COVID-19 2. Aucune preuve de son efficacité clinique pour la prise en charge de patients présentant une COVID-19 asymptomatique, légère, modérée ou sévère 3. Aucune donnée de sécurité concernant l’utilisation de l’ivermectine pour la COVID-19 dans la majorité des études publié
more
On this page we provide an overview of excess mortality along with charts to explore the data. You can learn in more depth about different measures of excess mortality, their strengths and limitations, and their comparability across countries
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform...ation and a recommendation on hydroxychloroquine. It follows the publication of six trials synthesized in a living network meta-analysis (NMA).
more
This e-learning course is designed for front-line managers of institutions hosting or serving people who are medially or socially vulnerable to the impact of COVID-19. It is a non-moderated and self-paced course. You can decide when to start it, interrupt and resume to continue at any time. In total..., the course is designed to take from 1 to 3 hours to complete. The content of this course is available in all 24 EU official working languages.
more
Mars 2020. Recommendations selon les differentes phases
Contact tracing is a key element of WHO’s recommended approach to control the spread of COVID-19 by breaking the chains of human-to-human transmission.
This document provides guidance to health authorities at all levels to improve the success rate of contact tracing by informing efforts with RCCE... principles, evidence and activities, and provides ready-to-use tools for professionals involved in contact-tracing efforts to inform their practices with RCCE principles and likewise improve their success rate.
more
1 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Diese Faktenboxen sollen Ihnen helfen, Nutzen und Schaden einer Schutzimpfung gegen COVID-19 abzuwägen. Die Informationen und Zahlen stellen keine endgültige Bewertung dar. Sie basieren auf den derzeit besten wissenschaftlichen Erkenntnissen.
Reseña normativa
24 de Julio de 2020
La pandemia de COVID-19 ha afectado de manera desproporcionada a las personas de edad y especialmente a aquellas que viven
en los centros de atención de larga estancia. En muchos países, los datos demuestran que más del 40% de las muertes relacionadas
con... la COVID-19 se hallaban vinculadas a los centros de atención de larga estancia, con cifras de hasta el 80% en algunos países
de ingresos altos.
more
African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
Note d’orientation
24 juillet 2020
La pandémie de COVID-19 a touché de façon disproportionnée les personnes âgées, en particulier celles qui vivent dans des établissements de soins de longue durée. Dans de nombreux pays, les données probantes montrent que plus de 40 % des décès associ...és à la COVID-19 ont eu lieu dans des établissements de soins de longue durée, les chiffres pouvant atteindre 80 % dans certains pays à revenu élevé.
more